Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3

LABT’s announcement is all promise, no proof—investors should wait for real data.

What the company is saying

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) is positioning itself as a biotech innovator targeting a major unmet need: infected diabetic foot ulcers (iDFU), which they claim affects millions globally. The company’s core narrative is that Nu-3, their lead Bisphosphocin® antimicrobial, is a novel solution with a unique mechanism of action capable of rapidly eliminating a broad spectrum of bacteria, including resistant strains and biofilms. They want investors to believe that the initiation of a Phase 2 clinical program, in partnership with Professional Education and Research Institute LLC (PERI) as CRO, marks a pivotal step toward addressing antibiotic resistance and capturing a large market. The announcement is heavy on forward-looking statements, emphasizing the strategic alignment with PERI, the anticipated efficiency of patient recruitment, and the potential for high-quality data generation. The language is assertive and optimistic, repeatedly highlighting the novelty and promise of Nu-3, but it avoids any mention of financials, regulatory timelines, or concrete clinical endpoints. Notably, the company buries or omits any discussion of risks, prior clinical results, or the specifics of trial design beyond dosing regimens. The tone is confident, bordering on promotional, with management projecting certainty about future impact without providing supporting evidence. Among notable individuals, Charles Zelen, DPM, FACFAS, is identified as a practicing podiatrist with deep ties to the diabetic foot care community, which lends some clinical credibility, but there is no indication of institutional investment or external validation. This narrative fits a classic early-stage biotech IR strategy: focus on unmet need, scientific novelty, and operational milestones, while deferring hard questions about efficacy, safety, and commercialization. There is no evidence of a shift in messaging, as no historical communications are referenced.

What the data suggests

The only concrete data disclosed is operational: LABT has signed an agreement with PERI to serve as CRO for the upcoming Phase 2 clinical program of Nu-3. The announcement specifies that the Phase 2a study will compare 2%, 5%, and 10% gel concentrations, followed by a Phase 2b study evaluating dosing frequency and placebo comparison, but provides no enrollment numbers, timelines, or endpoints. There are no financial figures, revenue, cost data, or period-over-period metrics—making it impossible to assess the company’s financial trajectory or health. The gap between claims and evidence is stark: while the company touts Nu-3’s unique mechanism and broad-spectrum efficacy, no clinical or quantitative data are provided to substantiate these assertions. There is no mention of whether prior targets or guidance have been met, nor any historical context for the current milestone. The quality of disclosure is poor from a financial analysis perspective, as key metrics such as cash runway, R&D spend, or even trial budget are entirely absent. An independent analyst, looking only at the numbers, would conclude that the company has taken a necessary but routine operational step—engaging a CRO for a mid-stage trial—without demonstrating any clinical or commercial progress. The lack of data means the announcement is not actionable for investors seeking evidence-based signals.

Analysis

The announcement is framed in highly positive language, emphasizing the strategic partnership and the potential impact of Nu-3 on a significant unmet medical need. However, the only realised milestone is the signing of an agreement with a CRO to initiate a Phase 2 clinical program; all other claims are forward-looking, including the anticipated benefits, clinical outcomes, and market impact. There is no disclosure of financial terms, timelines for trial completion, or regulatory milestones, and no clinical efficacy or safety data is presented. The capital intensity flag is set because entering a Phase 2 trial implies substantial expenditure, but no immediate earnings or value creation is demonstrated. The narrative inflates the signal by projecting future success and broad impact without supporting data or near-term deliverables. The evidence supports only the operational step of engaging a CRO, not the broader claims.

Risk flags

• ●The majority of claims are forward-looking, with no clinical efficacy or safety data disclosed. This matters because investors are being asked to buy into a narrative of future success without any present evidence, increasing the risk of disappointment if trials underperform.
• ●Capital intensity is high, as entering a Phase 2 clinical program with a CRO implies substantial R&D expenditure. Without disclosure of cash position or funding sources, there is a risk of future dilution or financing shortfalls.
• ●Operational risk is significant: the success of the program depends on efficient patient recruitment, trial execution, and data quality, all of which are promised but not substantiated with metrics or track record.
• ●Disclosure risk is acute, as the announcement omits all financial data, trial timelines, and regulatory milestones. This lack of transparency makes it difficult for investors to assess the company’s true position or progress.
• ●Pattern-based risk is present: the announcement uses aspirational language and highlights potential impact, but provides no measurable progress or historical context, a common red flag in early-stage biotech communications.
• ●Timeline/execution risk is high, as the path from Phase 2 initiation to market is long and fraught with potential setbacks, including trial failure, regulatory hurdles, and competitive developments.
• ●There is no mention of geographic scope, trial site locations, or regulatory jurisdiction, which could lead to inconsistencies or surprises regarding trial feasibility or approval pathways.
• ●While Charles Zelen, DPM, FACFAS, is cited as a notable individual with clinical expertise, his involvement does not guarantee trial success or commercial adoption, and there is no evidence of institutional investment or partnership.

Bottom line

For investors, this announcement signals that LABT has taken a necessary operational step—engaging a CRO to initiate a Phase 2 trial for Nu-3—but offers no new evidence of clinical or commercial progress. The company’s narrative is ambitious, emphasizing unmet need and scientific novelty, but is not supported by any disclosed data, financials, or timelines. The absence of clinical results, cash position, or even trial endpoints means the credibility of the narrative is low; it is essentially a promise of future value with no near-term deliverables. The involvement of Charles Zelen, DPM, FACFAS, adds some clinical legitimacy, but does not constitute institutional validation or guarantee of success. To change this assessment, the company would need to disclose concrete clinical data (e.g., Phase 2a results), funding arrangements, or binding commercial partnerships. Investors should watch for actual trial enrollment, interim data releases, and any updates on cash runway or financing in the next reporting period. At this stage, the information is not actionable for investment—monitoring is warranted, but there is no basis for a buy or sell decision. The single most important takeaway is that LABT’s announcement is all about potential, not performance; until real data emerges, the risk profile remains high and the signal weak.

Announcement summary

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) announced it has entered into an agreement with Professional Education and Research Institute LLC (PERI) to serve as the contract research organization for its upcoming Phase 2 clinical program of Nu-3. The Phase 2 program will evaluate the safety and efficacy of Nu-3, a novel Bisphosphocin® antimicrobial, in patients with mildly infected diabetic foot ulcers (iDFU). The program will begin with a single-blinded Phase 2a study comparing 2%, 5%, and 10% gel concentrations, followed by a Phase 2b study evaluating different gel concentrations as once-a-day or twice-a-day treatments versus placebo. This partnership aims to address the significant unmet medical need in the iDFU market, which affects millions of patients worldwide.

Disagree with this article?